Kuntaman and Sanarto Santoso and Hendro Wahjono and Ni Made Mertaniasih and Endang S. Lestari and Helmia Farida and Rebriarina Hapsari and Stefani Candra Firmanti and Noorhamdani AS and Dewi Santosoningsih and Priyo Budi Purwono and Deby Kusumaningrum (2011) Pola Sensitivitas bakteri penghasil Extended Spectrum Beta Lactamase terhadap Enam Antibiotik yang biasa dipergunakan pada pengobatan di Klinik. Journal of the Indonesian Medical Association (Majalah Kedokteran Indonesia), 61 (12). pp. 482-486. ISSN 2089-1067

	Text (Similarity) The Sensitivity Pattern of Extended Spectrum Beta Lactamase-Producing Bacteria Against Six Antibiotics that Routinely Used in Clinical Setting.pdf Download (2MB)
	Text (Peer Review) The sensitivity Pattern of Extended .pdf Download (3MB)
	Text (Artikel) The Sensitivity Pattern of Extended Spectrum Beta Lactamase-Producing Bacteria Against Six Antibiotics that Routinely Used in Clinical Setting.pdf Download (82kB)

Abstract

The validated study of extended-spectrum β-lactamase (ESBL) producing bacteria in Indonesia is scarce. Multi-centre study on susceptibility of ESBLs producers is our point of view. A survey was carried out in three teaching hospitals in Surabaya (Dr. Soetomo), Malang (Dr. Saiful Anwar) and Semarang (Dr. Kariadi). Clinical ESBL-producers were collected in over four months period (January to April 2010) up to 300 strains. The susceptibility against 6 antibiotics below were used as a point of view in analysis. As many as 300 isolates were collected, 140 (Surabaya), 85 (Semarang) and 75 (Malang) respectively. The three most prevalent ESBL producers were: E. coli (42.7%), Klebsiella pneumoniae (47.3%) and Enterobacter spp (7%). The other 9 strains were: Citrobacter spp, Klebsiella oxytoca, Proteus mirabilis and Serratia spp. The susceptibility analysis was then performed on the three most prevalent isolates. The sensitivity rate of E. coli, Klebsiella pneumoniae and Enterobacter spp against tested antibiotics were 3%, 4% and 5% for cefotaxim; 91%, 87% and 90% for Amikacin; 27%, 54% and 43% for Ciprofloxacin; 98%, 93% and 100% for Cefoperason-Sulbactam; 100%, 96% and 100% for Meropenem; 95%, 94% and 86% for Fosfomycin. As a conclusion, we found that amikacin, cefoperason-sulbactam, meropenem and fosfomycin, are prospective for emperic therapy in clinical setting of health services where ESBL producing bacteria were prevalent as causative

Actions (login required)

View Item